Lincomycin Hydrochloride Eye Drops

This product has high antibacterial activity against common aerobic Gram-positive bacteria, such as Staphylococcus aureus (including those resistant to penicillin G), Staphylococcus epidermidis, β-hemolytic Streptococcus, viridans Streptococcus and Streptococcus pneumoniae. It has good antibacterial effect on anaerobic bacteria, including Clostridium diphtheriae, and Clostridium perfringens. It has no activity against Gram-negative bacteria such as Enterococcus, meningococci, Neisseria gonorrhoeae, and Haemophilus influenzae, as well as fungi. There is no cross-resistance between this product and penicillin, chloramphenicol, cephalosporins and tetracyclines, and there is partial cross-resistance with macrolides. This product acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria.

The main ingredient of this product is lincomycin hydrochloride

This product is a colorless clear liquid.

This product is mainly used for conjunctivitis, keratitis, etc. caused by sensitive bacteria infection.

Intramuscular injection: 0.6-1.2g per day for adults, 10-20mg/kg per day for children, divided into several injections. Intravenous drip: Generally, 0.6g per time for adults, once every 8 hours or 12 hours, each 0.6g is dissolved in 100-200ml of infusion solution, drip for 1-2 hours. For children, 10-20mg/kg per day is based on body weight. It should be noted that each 0.6g is dissolved in no less than 100ml of solution for intravenous drip, and the drip time is no less than 1 hour. It is not necessary for infants under 4 weeks old

1. Gastrointestinal reactions: symptoms such as nausea, vomiting, abdominal pain, diarrhea, etc.; severe cases may include abdominal cramps, abdominal tenderness, severe diarrhea (watery or purulent), accompanied by fever, abnormal thirst and fatigue (pseudomembranous colitis); diarrhea, enteritis and pseudomembranous colitis may occur in the early stage of medication or several weeks after discontinuation of medication. 2. Blood system: leukopenia, neutropenia, neutropenia and thrombocytopenia may occur occasionally, and aplastic anemia is rare. 3. Allergic reactions: rash, itching, etc. may be seen, and urticaria, angioedema and serum sickness reactions may occasionally be seen. There are rare reports of epidermal excoriation, bullous dermatitis, erythema multiforme and S-J syndrome. 4. There are occasional reports of jaundice caused by the use of this product. 5. Hypotension, electrocardiogram changes and even heart and respiratory arrest may occur during rapid infusion of this product.

Contraindicated in patients with a history of allergy to lincomycin and clindamycin

Precautions for children: Not for use in infants under 1 month old. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: Not yet clear.

1. It can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory depression or paralysis (apnea). Caution should be taken when used in combination during or after surgery. Treatment with anticholinesterase drugs or calcium salts is expected to be effective. 2. When used in combination with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay, this product may cause pseudomembranous colitis with severe watery diarrhea during the course of treatment or even a few weeks after the course of treatment. Because it can delay the excretion of colonic endotoxins, thereby causing prolonged and aggravated diarrhea, antiperistaltic antidiarrheal drugs should not be used in combination. When this product is used in combination with antidiarrheal drugs containing white clay, the absorption of the former will be significantly reduced. Therefore, the two should not be taken at the same time and a certain time interval (at least 2 hours) is required. 3. This product has a neuromuscular blocking effect. When used in combination with anti-myasthenic drugs, the latter will weaken the effect on skeletal muscles. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted when used in combination. 4. Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the latter from binding to the bacterial ribosome 50S subunit. In vitro tests show that lincomycin and erythromycin have antagonistic effects, so lincomycin should not be used in combination with chloramphenicol or erythromycin. 5. When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may lead to prolonged respiratory depression or respiratory paralysis (apnea) due to the cumulative phenomenon, so the patient must be closely observed or monitored. 6. This product can enhance the effect of neuromuscular blocking drugs, and the two should be avoided in combination. 7. It is incompatible with neomycin and kanamycin when used in the same bottle for intravenous infusion.

Sealed storage

8ml:0.2g

24 months

Chongqing KERUI Pharmaceutical (GROUP) Co., Ltd.

• Founded in:

  1999-03-03

• Address:

  No. 2 Dashizhi Road, Nan'an Economic and Technological Development Zone, Chongqing

• Tax NO.:

  915001082031636780

• Registered Funds:

  110.6375 million yuan

• Website:

  Log in to view

• Email:

  Log in to view